IBJNews

Lilly, other drugmakers to keep paying doctors

Back to TopCommentsE-mailPrintBookmark and Share

Eli Lilly and Co., Pfizer Inc., Sanofi and other large drugmakers will keep paying doctors to give talks about their products, leaving GlaxoSmithKline Plc alone for now in its decision to halt such compensation.

Glaxo changed its policy after Chinese authorities accused the company of using cash and sexual favors to bribe doctors and health officials to promote product sales. The company’s competitors say physicians often remain the best source of information for their colleagues and should be rewarded for their work.

The industry is facing greater scrutiny about fees to doctors after paying at least $12.9 billion in fines and settlements in the U.S. alone since 2009, mostly over improper marketing, according to the U.S. Justice Department.

Ensuring transparency for physician compensation among the companies that continue the practice is paramount, said Nikos Dedes, a member of the management board of the European Medicines Agency and founder of Greek HIV patient advocacy group Positive Voice.

“This should happen in a much faster manner,” Dedes said in a telephone interview from Athens. “There should be some pressure.”

Doctors prefer to learn about treatment options from their peers, and payments make sense given the time and energy required to understand and share information, according to companies that plan to keep remunerating physicians.

Fair compensation

“Few products in the world are as complex as an innovative medicine,” said Scott MacGregor, a spokesman for Indianapolis-based Lilly. Glaxo’s move won’t change how Lilly does business, MacGregor said.

Work done by health-care professionals “needs to be compensated in a fair and transparent manner,” according to Paris-based Sanofi.

Pfizer, the world’s biggest drugmaker, is “committed to fairly compensating health-care professionals, clinical investigators and institutions for the work they do,” Dean Mastrojohn, a spokesman for the company, said in an e-mail.

Bristol-Myers Squibb Co., based in New York like Pfizer, said it properly compensates physicians for their time. The company supports “appropriate efforts to increase transparency.”

Dublin-based Shire Plc, the biggest maker of drugs for attention-deficit disorder, said “we appropriately compensate” physicians and researchers for their expertise.

The industry has taken steps toward disclosure this year. Drugmakers who belong to the European Federation of Pharmaceutical Industries and Associations, which include Sanofi, Lilly, Bristol-Myers and Pfizer, are being pushed to report payments under a rule set this year by the trade group.

Dollars for docs

The European rule gives drugmakers until 2016 to disclose payments for the first time from the preceding year.

In the U.S., the Patient Protection and Affordable Care Act of 2010 required companies to track payments starting Aug. 1, and report the information to the government for annual publication starting next year.

Some drugmakers are already publishing data for the U.S., in some cases because of settlement deal requirements. ProPublica, a not-for-profit investigative news organization, tracks that data in a project called Dollars for Docs. It shows that Glaxo had already pared back its payments.

Glaxo said in 2011 it changed its U.S. marketing practices by eliminating individual sales goals, after facing government investigations over its marketing of diabetes drug Avandia and other medicines. It settled those claims in 2012 by paying a record $3 billion, only to face allegations of bribery last summer in China. The London-based company said earlier this week it would abolish individual sales goals worldwide by 2015.

Exceeding Pfizer

Glaxo’s spending on speaking fees dropped more than 80 percent from 2010 to about $2.5 million in each of the first three quarters of last year, according to ProPublica.

That’s more than the $2.08 million per quarter spent by Pfizer. Lilly spent $5.94 million per quarter on speaking fees per quarter in the same 2012 time period.

By way of comparison, Merck & Co. spent $4.81 million, and AstraZeneca Plc paid $4.06 million.

Neither company answered calls and e-mails seeking comment.

Bayer AG, Roche Holding AG and Novartis AG didn’t comment on whether they planned to follow Glaxo’s lead. Bayer of Leverkusen, Germany, said in a statement the company abides by the law and guidelines laid out by its trade associations.

“We’re observing these developments very closely,” said Daniel Grotzky, a spokesman for Basel, Switzerland-based Roche. “Obviously the overall trend is toward more transparency.”

ADVERTISEMENT

Post a comment to this story

COMMENTS POLICY
We reserve the right to remove any post that we feel is obscene, profane, vulgar, racist, sexually explicit, abusive, or hateful.
 
You are legally responsible for what you post and your anonymity is not guaranteed.
 
Posts that insult, defame, threaten, harass or abuse other readers or people mentioned in IBJ editorial content are also subject to removal. Please respect the privacy of individuals and refrain from posting personal information.
 
No solicitations, spamming or advertisements are allowed. Readers may post links to other informational websites that are relevant to the topic at hand, but please do not link to objectionable material.
 
We may remove messages that are unrelated to the topic, encourage illegal activity, use all capital letters or are unreadable.
 

Messages that are flagged by readers as objectionable will be reviewed and may or may not be removed. Please do not flag a post simply because you disagree with it.

Sponsored by
ADVERTISEMENT

facebook - twitter on Facebook & Twitter

Follow on TwitterFollow IBJ on Facebook:
Follow on TwitterFollow IBJ's Tweets on these topics:
 
Subscribe to IBJ
  1. Can your dog sign a marriage license or personally state that he wishes to join you in a legal union? If not then no, you cannot marry him. When you teach him to read, write, and speak a discernible language, then maybe you'll have a reasonable argument. Thanks for playing!

  2. Look no further than Mike Rowe, the former host of dirty jobs, who was also a classically trained singer.

  3. Current law states income taxes are paid to the county of residence not county of income source. The most likely scenario would be some alteration of the income tax distribution formula so money earned in Marion co. would go to Marion Co by residents of other counties would partially be distributed to Marion co. as opposed to now where the entirety is held by the resident's county.

  4. This is more same-old, same-old from a new generation of non-progressive 'progressives and fear mongers. One only needs to look at the economic havoc being experienced in California to understand the effect of drought on economies and people's lives. The same mindset in California turned a blind eye to the growth of population and water needs in California, defeating proposal after proposal to build reservoirs, improve water storage and delivery infrastructure...and the price now being paid for putting the demands of a raucous minority ahead of the needs of many. Some people never, never learn..

  5. I wonder if I can marry him too? Considering we are both males, wouldn't that be a same sex marriage as well? If they don't honor it, I'll scream discrimination just like all these people have....

ADVERTISEMENT